Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

A descriptive follow-up interview study assessing patient-centred outcomes: Salford Lung Study in Asthma (SLS Asthma).

Doward L, Svedsater H, Whalley D, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N.

NPJ Prim Care Respir Med. 2019 Aug 15;29(1):31. doi: 10.1038/s41533-019-0142-x.

2.

Chronic obstructive pulmonary disease exacerbation episodes derived from electronic health record data validated using clinical trial data.

Sperrin M, Webb DJ, Patel P, Davis KJ, Collier S, Pate A, Leather DA, Pimenta JM.

Pharmacoepidemiol Drug Saf. 2019 Aug 5. doi: 10.1002/pds.4883. [Epub ahead of print]

PMID:
31385428
3.

Can medicines development improve outcomes in asthma and chronic obstructive pulmonary disease management by driving effectiveness?

Leather DA, Yates L, Svedsater H, Jacques L, Collier S, Powell D, Jones R.

Respir Res. 2019 Aug 2;20(1):173. doi: 10.1186/s12931-019-1127-6.

4.

Follow-up interviews from The Salford Lung Study (COPD) and analyses per treatment and exacerbations.

Whalley D, Svedsater H, Doward L, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N.

NPJ Prim Care Respir Med. 2019 May 9;29(1):20. doi: 10.1038/s41533-019-0123-0.

5.

Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.

Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.

Respir Med. 2019 Feb;147:58-65. doi: 10.1016/j.rmed.2018.12.016. Epub 2019 Jan 10.

6.

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.

Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A.

Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6.

7.

Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study.

Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA.

J Asthma. 2019 Jul;56(7):748-757. doi: 10.1080/02770903.2018.1490751. Epub 2018 Oct 16.

PMID:
29972089
8.

Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability.

Woodcock A, Boucot I, Leather DA, Crawford J, Collier S, Bakerly ND, Hilton E, Vestbo J.

Eur Respir J. 2018 Feb 21;51(2). pii: 1701531. doi: 10.1183/13993003.01531-2017. Print 2018 Feb.

9.

Putting patients in control of data from electronic health records.

New JP, Leather D, Bakerly ND, McCrae J, Gibson JM.

BMJ. 2018 Jan 2;360:j5554. doi: 10.1136/bmj.j5554. No abstract available.

PMID:
29295813
10.

Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes.

Doward L, Svedsater H, Whalley D, Crawford R, Leather D, Lay-Flurrie J, Bosanquet N.

NPJ Prim Care Respir Med. 2017 Dec 15;27(1):66. doi: 10.1038/s41533-017-0066-2.

11.

Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys.

Svedsater H, Leather D, Robinson T, Doll H, Nafees B, Bradshaw L.

Respir Med. 2017 Nov;132:76-83. doi: 10.1016/j.rmed.2017.09.010. Epub 2017 Sep 27.

12.

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.

Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D; Salford Lung Study Investigators.

Lancet. 2017 Nov 18;390(10109):2247-2255. doi: 10.1016/S0140-6736(17)32397-8. Epub 2017 Sep 10. Erratum in: Lancet. 2017 Nov 18;390(10109):e40. Lancet. 2018 Feb 3;391(10119):430.

PMID:
28903864
13.

Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms: Post hoc analyses of three randomized controlled trials.

Kerwin E, Barnes N, Gibbs M, Leather D, Forth R, Jacques L, Yates LJ.

J Asthma. 2018 Aug;55(8):890-897. doi: 10.1080/02770903.2017.1362429. Epub 2018 Jul 24.

PMID:
28783413
14.

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma-mixed treatment comparisons of clinical efficacy.

Svedsater H, Stynes G, Wex J, Frith L, Leather D, Castelnuovo E, Detry M, Berry S.

Asthma Res Pract. 2016 Feb 8;2:4. doi: 10.1186/s40733-015-0016-0. eCollection 2016.

15.

Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study.

Collier S, Harvey C, Brewster J, Bakerly ND, Elkhenini HF, Stanciu R, Williams C, Brereton J, New JP, McCrae J, McCorkindale S, Leather D.

Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):344-352. doi: 10.1002/pds.4118. Epub 2016 Nov 1.

16.

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A; Salford Lung Study Investigators.

N Engl J Med. 2016 Sep 29;375(13):1253-60. doi: 10.1056/NEJMoa1608033. Epub 2016 Sep 4.

17.

The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma.

Woodcock A, Bakerly ND, New JP, Gibson JM, Wu W, Vestbo J, Leather D.

BMC Pulm Med. 2015 Dec 10;15:160. doi: 10.1186/s12890-015-0150-8.

18.

The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.

Bakerly ND, Woodcock A, New JP, Gibson JM, Wu W, Leather D, Vestbo J.

Respir Res. 2015 Sep 4;16:101. doi: 10.1186/s12931-015-0267-6.

19.

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.

Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.

Respir Res. 2015 Feb 15;16:25. doi: 10.1186/s12931-015-0184-8. Review.

20.

Obtaining real-world evidence: the Salford Lung Study.

New JP, Bakerly ND, Leather D, Woodcock A.

Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6. Erratum in: Thorax. 2015 Oct;70(10):1008.

21.

Novel study design to assess the utility of the copd assessment test in a primary care setting.

Gruffydd-Jones K, Marsden H, Holmes S, Kardos P, Escamilla R, Dal Negro R, Roberts J, Nadeau G, Leather D, Jones P.

BMC Med Res Methodol. 2013 May 10;13:63. doi: 10.1186/1471-2288-13-63.

22.

Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled trial.

Gruffydd-Jones K, Marsden HC, Holmes S, Kardos P, Escamilla R, Dal Negro R, Roberts J, Nadeau G, Vasselle M, Leather DA, Jones P.

Prim Care Respir J. 2013 Mar;22(1):37-43. doi: 10.4104/pcrj.2013.00001.

23.

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H; ASSERT Study Group.

Clin Infect Dis. 2010 Oct 15;51(8):963-72. doi: 10.1086/656417.

PMID:
20828304
24.

High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing.

Thomas M, Turner S, Leather D, Price D.

Br J Gen Pract. 2006 Oct;56(531):788-90.

25.

High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study.

Thomas M, Leather D, Price D.

Prim Care Respir J. 2006 Jun;15(3):166-72. Epub 2006 Apr 11.

26.

Paediatricians and the pharmaceutical industry: an industry perspective of the challenges ahead.

Leather DA, Davis SC.

Paediatr Respir Rev. 2006 Mar;7(1):60-6. Review.

PMID:
16473819
27.

AIDS publicity: some experiences from Scotland.

Hastings GB, Leather DS, Scott AC.

Br Med J (Clin Res Ed). 1987 Jan 3;294(6563):48-9. No abstract available.

28.

The speech of the cerebral palsied child.

LEATHER D.

Folia Phoniatr (Basel). 1954;6(1):38-42. No abstract available.

PMID:
13151253

Supplemental Content

Loading ...
Support Center